(CercleFinance.com) – Berenberg reiterated its purchase recommendation on UCB on Thursday, while increasing its price target on the shares of the Belgian pharmaceutical group from 120 to 130 euros.
In a research note, the analyst underlines that the group benefited from a solid start to the year after a transition phase which penalized both its financial performance and its stock market performance.
With four new product launches currently underway, the laboratory is getting into working order and has a clear path to benefit from a future period of growth, he concludes.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
